The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BBNX | -26% | N/A | N/A | -57% |
| S&P | +20.12% | +68.19% | +10.95% | +9% |
Beta Bionics is a biotechnology company that develops an integrated bionic pancreas system called the iLet. The iLet Bionic Pancreas System was granted breakthrough designation in all configurations (insulin-only, glucagon-only, and bihormonal), including use with Zealand Pharma’s dasiglucagon, a glucagon analogue with a stability profile in a ready-to-use aqueous solution. It also offers a bionic pancreas device for glucose metabolism to the diabetes community.
No news articles found for Beta Bionics.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $32.12M | 57.1% |
| Gross Profit | $18.94M | 62.1% |
| Gross Margin | 58.98% | 1.8% |
| Market Cap | $1.34B | 0.0% |
| Market Cap / Employee | $3.17M | 0.0% |
| Employees | 423 | 45.4% |
| Net Income | -$13,466.00K | 25.6% |
| EBITDA | -$15,587.00K | -24.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $31.68M | 4.1% |
| Accounts Receivable | $17.12M | 42.7% |
| Inventory | 21.7 | 63.1% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $5.37M | -6.3% |
| Short Term Debt | $1.94M | 26.7% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -30.60% | 11.6% |
| Return On Invested Capital | -179.78% | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$10,530.00K | 29.0% |
| Operating Free Cash Flow | -$8,627.00K | 39.6% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -2.16 | 2.01 | 2.86 | 4.55 | - |
| Price to Sales | 7.60 | 8.11 | 9.79 | 13.43 | - |
| Price to Tangible Book Value | -2.16 | 2.01 | 2.86 | 4.55 | - |
| Enterprise Value to EBITDA | -16.97 | -20.28 | -39.49 | -72.80 | - |
| Return on Equity | -81.3% | -47.5% | -40.3% | - | |
| Total Debt | $6.97M | $6.69M | $7.69M | $7.30M | 0.66% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
